• Home
  • NEW DAY MEDICINE
  • 4 (78) 2025
  • 121 - 4 (78) 2025 - Mukhammedaminova D.T., Nasirova Kh.K. - INHIBIN A AS A PREDICTOR OF RECURRENT PREGNANCY LOSS IN WOMEN WITH HYPERPROLACTINEMIA

121 - 4 (78) 2025 - Mukhammedaminova D.T., Nasirova Kh.K. - INHIBIN A AS A PREDICTOR OF RECURRENT PREGNANCY LOSS IN WOMEN WITH HYPERPROLACTINEMIA

INHIBIN A AS A PREDICTOR OF RECURRENT PREGNANCY LOSS IN WOMEN WITH HYPERPROLACTINEMIA

Mukhammedaminova D.T. - Tashkent Pediatric Medical Institute

Nasirova Kh.K. - Tashkent Pediatric Medical Institute

Mirzaeva U.Z. - Tashkent Pediatric Medical Institute

Maksudova D.R. - Tashkent Pediatric Medical Institute

Resume

This article discusses the role of Inhibin A as a biomarker for predicting the development of recurrent miscarriage (RM). RM is a significant clinical issue that affects both the physical and psychological health of women. Research indicates that Inhibin A, a hormone secreted by ovarian follicles and the placenta, plays a critical role in regulating reproductive function and may serve as an indicator of adverse pregnancy outcomes. Monitoring Inhibin A levels at various stages of gestation enables the identification of high-risk groups and facilitates the timely adjustment of pregnancy management strategies.

Keywords: Hyperprolactinemia, recurrent miscarriage, prolactin, inhibin, pregnancy.

First page

694

Last page

699

For citation:Mukhammedaminova D.T., Nasirova Kh.K., Mirzaeva U.Z., Maksudova D.R. - INHIBIN A AS A PREDICTOR OF RECURRENT PREGNANCY LOSS IN WOMEN WITH HYPERPROLACTINEMIA//New Day in Medicine 4(78)2025 694-699 https://newdayworldmedicine.com/en/new_day_medicine/4-78-2025

List of References

  1. Abdulkadyrova ZK, Abashova EI. Inhibin as a reproductive biomarker. Part 1. Journal of Obstetrics and Women’s Diseases. 2019;68(3):61-70. https://doi.org/10.17816/JOWD68361-70
  2. Abdulkadyrova ZK, Yarmolinskaya MI, Gzgzyan AM, et al. Inhibin as a reproductive biomarker. Part 2. Clinical significance of inhibins in reproductive medicine. Journal of Obstetrics and Women’s Diseases. 2019;68(5):91-106. https://doi.org/10.17816/JOWD68591-106
  3. Chester M.R., Tirlapur A. and Jayaprakasan K. (2022), Current management of recurrent pregnancy loss. Obstet Gynecol,24: 260-271. https://doi.org/10.1111/tog.12832
  4. Ciarmela P, Florio P, Toti P, et al. Expression of betaglycan in pregnant issues throughout gestation. Eur J Endocrinol. 2003:433-437 https://doi.org/10.1530/eje.0.1490433.
  5. Erol O, Süren D, Tutuş B, et al. Immunohistochemical analysis of E-cadherin, p53 and inhibin-α expression in hydatidiform mole and hydropic abortion. Pathol Oncol Res. 2016;22(3):515-521. https://doi.org/10.1007/s12253-015-0031-8.
  6. European Society of Human Reproduction and Embryology (ESHRE). Recurrent pregnancy loss. Strombeek-Bever: ESHRE; 2017 https://www.eshre.eu/Guidelines-and-Legal/Guidelines/Recurrent-pregnancy-loss.aspx Google Scholar
  7. Endocrine Abnormalities in RPL| Obgyn key. Дата обращения:15.01.2025 https://obgynkey.com/endocrine-abnormalities-in-rpl/
  8. Endocrine/Олина А.А. Неразвивающаяся беременность и гиперпролактинемия. РМЖ. Мать и дитя.2020; (2):64-69. DOI:10.32364/2618-8430-2020-3-64-69 https://www.rmj.ru/articles/akusherstvo/Nerazvivayuschayasya_beremennosty_i_giperprolaktinemiya_Esty_li_mesto_rastitelynym_preparatam_v_terapii/#ixzz8ZozpfcCW
  9. Jones RL, Salamonsen LA, Critchley HO, et al. Inhibin and activin subunits are differentially expressed in endometrial cells and leukocytes during the menstrual cycle, in early pregnancy and in women using progestin-only contraception. Mol Hum Reprod. 2000;6(12):1107-1117. https://doi.org/10.1093/molehr/6.12.1107
  10. Muttukrishna S, George L, Fowler PA, et al. Measurement of serum concentrations of inhibin-A (α-β A dimer) during human pregnancy. Clin Endocrinol (Oxf). 1995;42(4):391-397. https://doi.org/10.1111/j.1365-2265.1995.tb02648.x.
  11. Namwanje M, Brown CW. Activins and Inhibins: Roles in Development, Physiology, and Disease. Cold Spring Harb Perspect Biol. 2016;8(7):a021881. https://doi.org/10.1101/cshperspect.a02188
  12. Practice Committee of the American Society for Reproductive Medicine. Evaluation and treatment of recurrent pregnancy loss: a committee opinion. Fertil Steril 2012; 98: 1103–11.
  13. Royal College of Obstetricians and Gynaecologists (RCOG). The investigation and treatment of couples with recurrent first-trimester and second-trimester miscarriage. Green-top guideline No. 17. London: RCOG; 2011
  14. Sosnova E.A. Hyperprolactinemic syndrome. V.F. Snegirev Archives of Obstetrics and Gynecology, Russian journal. 2017; 4(1): 4—14. (In Russ.). DOI: http://dx.doi.org/10.18821/2313­8726­2017­4­1­4­14
  15. Stenvers KL, Findlay JK. Inhibins and activins: towards the future. A tribute to the late Professor Wylie W. Vale. Mol Cell Endocrinol. 2012;359(1-2):1. https://doi.org/10.1016/j.mce.2012.03.001
  16. Treetampinich C, O’Connor AE, MacLachlan V, et al. Maternal serum inhibin A concentrations in early pregnancy after IVF and embryo transfer reflect the corpus luteum contribution and pregnancy outcome. Hum Reprod. 2000;15(9):2028-2032. https://doi.org/10.1093/humrep/15.9.2028
  17. Turasheva A., Aimagambetova G., Ukybassova T., and et al. 2023. «Recurrent pregnancy loss etiology, risk factors, diagnosis, and management. Fresh look into a full box» Journal of clinical medicine 12, no.12:4074 https://doi.org/10.3390/jcm12124074
  18. Wijayarathna R, de Kretser DM. Activins in reproductive biology and beyond. Hum Reprod Update. 2016;22(3):342- 357. https://doi.org/10.1093/humupd/dmv058

    file

    download